Rosetta Genomics Ltd. (NASDAQ:ROSG) will release its earnings data after the market closes on Wednesday, November 30th. Analysts expect Rosetta Genomics to post earnings of ($0.17) per share for the quarter.
Rosetta Genomics (NASDAQ:ROSG) last posted its earnings results on Monday, September 26th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The company had revenue of $2.40 million for the quarter. Rosetta Genomics had a negative return on equity of 110.76% and a negative net margin of 163.54%. On average, analysts expect Rosetta Genomics to post $-0.6300 EPS for the current fiscal year and $-0.3700 EPS for the next fiscal year.
Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) opened at 0.6199 on Tuesday. The company’s market capitalization is $12.93 million. The company has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.95. Rosetta Genomics Ltd. has a 1-year low of $0.55 and a 1-year high of $1.60.
Separately, S&P Equity Research dropped their target price on shares of Rosetta Genomics from $0.94 to $0.82 in a report on Wednesday, September 7th.
A hedge fund recently raised its stake in Rosetta Genomics stock. Morgan Stanley increased its stake in shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) by 15.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 337,973 shares of the company’s stock after buying an additional 43,997 shares during the period. Morgan Stanley owned approximately 1.62% of Rosetta Genomics worth $281,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 4.56% of the company’s stock.
About Rosetta Genomics